Top Tweets for #lisraya

24 days ago

🚨#FDA Approval Update | A new treatment option for #Dermatomyositis The FDA has approved #Lisraya (#brepocitinib) as the first FDA-approved oral treatment for adults with dermatomyositis, a rare #autoimmune disease where the immune system attacks muscles and skin. 💊As a #TYK2/#JAK1 inhibitor, brepocitinib targets key signaling pathways involved in inflammation. 🔬The approval addresses a major unmet need for patients who have long relied on therapies not specifically for dermatomyositis. Read more: https://t.co/HOKSXc4HEf #FDAApproval #AutoimmuneDisease #Inflammation #ChronicInflammation #DrugDevelopment

MedChemExpress's tweet photo. 🚨#FDA Approval Update | A new treatment option for #Dermatomyositis

The FDA has approved #Lisraya (#brepocitinib) as the first FDA-approved oral treatment for adults with dermatomyositis, a rare #autoimmune disease where the immune system attacks muscles and skin.

💊As a #TYK2/#JAK1 inhibitor, brepocitinib targets key signaling pathways involved in inflammation.

🔬The approval addresses a major unmet need for patients who have long relied on therapies not specifically for dermatomyositis.

Read more: https://t.co/HOKSXc4HEf

#FDAApproval #AutoimmuneDisease #Inflammation #ChronicInflammation #DrugDevelopment

247

Sareum Holdings plc @Sareumplc

24 days ago

FDA’s approval of #Lisraya (#brepocitinib) marks the first oral therapy for dermatomyositis and first approval for a dual TYK2/JAK #inhibitor. This adds to the clinical validation for these inhibitors as we advance SDC-1801 through clinical development. https://t.co/ClylatacYz

712

Top Tweets for #lisraya

Last Seen Hashtags on Sotwe

Trends for you

Most Popular Users